Abstract: Objective To analyze the effect of trastuzumab combined with SOX regimen in advanced gastric cancer patients with positive human epidermal growth factor receptor 2 (HER-2) and the influence of serum tumor markers and immune function. Methods A total of 89 patients with advanced gastric cancer with HER-2 positive admitted to the First People's Hospital of Shangqiu City from August 2019 to July 2021 were selected as research objects and divided into conventional group and research group by lottery method. Forty-four patients in the conventional group received SOX regimen (oxaliplatin + Tizio) chemotherapy, and 45 patients in the study group were additionally given trastuzumab. After 4 courses of treatment, total response rate, serum tumor markers, immune function and adverse reactions were compared between the two groups. Result sThe total effective rate of the study group was 68.89%, which was higher than 47.73% of the conventional group (P<0.05). The serum levels of carbohydrate antigen 199 (CA199), carcinoembryonic antigen (CEA) and carbohydrate antigen 724 (CA724) in the study group were lower than those in the conventional group (P<0.05). The levels of CD8⁺, CD3⁺ and CD4⁺ in the study group were higher than those in the conventional group (P<0.05). The incidence of bone marrow suppression, gastrointestinal reaction, liver function injury and hand-foot syndrome were compared between the two groups (P>0.05). Conclusion Trastuzumab combined with SOX regimen is effective in the treatment of advanced gastric cancer patients with positive HER-2, which can effectively improve the treatment effect, reduce the level of serum tumor markers, inhibit the decline of immune function, and has high safety.

Key words: trastuzumab, SOX scheme, human epidermal growth factor receptor 2, advanced gastric cancer, tumor marker, immune function

摘要： 目的 分析人表皮生长因子受体2（HER-2）阳性晚期胃癌患者应用曲妥珠单抗联合SOX方案治疗的效果及血清肿瘤标志物及免疫功能的影响。方法 选取2019年8月~2021年7月期间商丘市第一人民医院收治的89例HER-2阳性晚期胃癌患者作为研究对象,以抽签法分为常规组与研究组。常规组44例给予SOX方案（奥沙利铂+替吉奥）化疗,研究组45例在此基础上增加曲妥珠单抗。4个疗程后,对比2组患者总缓解率、血清肿瘤标志物、免疫功能、不良反应。结果 研究组总有效率为68.89%,高于常规组的47.73%（P<0.05）;研究组患者血清糖类抗原199（CA199）、癌胚抗原（CEA）、糖类抗原724（CA724）水平均低于常规组（P<0.05）;研究组患者CD8⁺、CD3⁺、CD4⁺水平均高于常规组（P<0.05）;2组患者骨髓抑制、胃肠道反应、肝功能损伤、手足综合征发生率比较（P>0.05）。结论 曲妥珠单抗联合SOX方案可有效提高HER-2阳性晚期胃癌患者治疗效果,抑制免疫功能下降,下调血清肿瘤标志物表达,且安全性较高。

关键词: 曲妥珠单抗, SOX方案, 人表皮生长因子受体2, 晚期胃癌, 肿瘤标志物, 免疫功能